Additional Paid-In Capital
Alnylam Pharmaceuticals Additional Paid-In Capital increased by 1.1% to $7.60B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.3%, from $7.50B to $7.60B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows an upward trend with a 5.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
A consistent increase is common for growth companies that frequently issue stock-based compensation or raise capital through equity markets.
Detailed definition
This represents the excess amount paid by investors for common shares above their stated par value. It is a critical com...
Peer comparison
This is a standard equity account for all publicly traded corporations, representing the cumulative historical premium paid by investors.
equity_additional_paid_in_capital_common_stockHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.86B | $5.97B | $6.06B | $6.12B | $6.17B | $6.34B | $6.45B | $6.52B | $6.65B | $6.74B | $6.81B | $6.88B | $7.12B | $7.26B | $7.39B | $7.50B | $7.69B | $7.41B | $7.51B | $7.60B |
| QoQ Change | — | +1.8% | +1.5% | +1.0% | +0.9% | +2.7% | +1.9% | +1.0% | +1.9% | +1.4% | +1.1% | +1.0% | +3.5% | +1.9% | +1.8% | +1.5% | +2.6% | -3.6% | +1.3% | +1.1% |
| YoY Change | — | — | — | — | +5.3% | +6.2% | +6.5% | +6.6% | +7.7% | +6.3% | +5.5% | +5.5% | +7.2% | +7.8% | +8.5% | +8.9% | +8.0% | +2.1% | +1.7% | +1.3% |
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's additional paid-in capital?
- Alnylam Pharmaceuticals (ALNY) reported additional paid-in capital of $7.60B in Q1 2026.
- How has Alnylam Pharmaceuticals's additional paid-in capital changed year-over-year?
- Alnylam Pharmaceuticals's additional paid-in capital increased by 1.3% year-over-year, from $7.50B to $7.60B.
- What is the long-term trend for Alnylam Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's additional paid-in capital has grown at a 5.9% compound annual growth rate (CAGR), from $5.64B to $7.51B.
- What does additional paid-in capital mean?
- The total amount of capital received from shareholders in excess of the nominal par value of the stock.